Silva-Santos and colleagues provide in vivo preclinical evidence supporting a therapeutic use of Delta One T cells to tackle colorectal cancer and propose activating natural killer cell receptor NKG2D and blocking immune checkpoint receptors as possible combination therapies.
- Rafael Blanco-Domínguez
- Leandro Barros
- Bruno Silva-Santos
